# First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

> **NCT05489237** · PHASE1 · RECRUITING · sponsor: **IDRX, Inc., a wholly owned subsidiary of GSK, LLC** · enrollment: 278 (estimated)

## Conditions studied

- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumor (GIST)
- Digestive System Disease
- Gastrointestinal Diseases
- Metastatic Cancer

## Interventions

- **DRUG:** IDRX-42

## Key facts

- **NCT ID:** NCT05489237
- **Lead sponsor:** IDRX, Inc., a wholly owned subsidiary of GSK, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-03
- **Primary completion:** 2027-03-10
- **Final completion:** 2028-06-28
- **Target enrollment:** 278 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489237, "First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05489237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*